Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo attack on tough liver cancer: radiation beads then immunotherapy

NCT ID NCT07122089

First seen May 07, 2026 · Last updated May 21, 2026 · Updated 5 times

Summary

This study tests a two-step treatment for people with advanced liver cancer that has spread into the main liver vein (portal vein thrombosis). First, tiny radioactive beads are injected into the liver to shrink the tumor from inside. Then, two immunotherapy drugs are given to help the immune system fight any remaining cancer. The goal is to see if this combination works better than current treatments. About 80 adults with this specific type of liver cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Grenoble

    ACTIVE_NOT_RECRUITING

    Grenoble, France

  • CHU de Lille

    ACTIVE_NOT_RECRUITING

    Lille, France

  • CHU de Montpellier

    ACTIVE_NOT_RECRUITING

    Montpellier, France

  • CHU de Nice

    ACTIVE_NOT_RECRUITING

    Nice, France

  • Centre Eugène Marquis

    RECRUITING

    Rennes, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • La Timone

    NOT_YET_RECRUITING

    Marseille, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.